Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

International Journal of Molecular Sciences

Tina Bøgelund Kristensen¹  Malin L. T. Knutsson¹  Markus Wehland⁴  Britt Elmedal Laursen³  Daniela Grimm¹  Elisabeth Warnke⁴  Nils E. Magnusson² 

[1] Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark; E-Mails:;Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Nørrebrogade 44, Aarhus C 8000, Denmark; E-Mail:;Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C 8000, Denmark; E-Mail:;Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany; E-Mails:

关键词: breast cancer;    anti-angiogenic therapy;    biomarkers;    vascular endothelial growth factor;   

DOI  :  10.3390/ijms151223024

来源: mdpi

【 摘 要 】

Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.